Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 16,173 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active control Clear all
Completed Not applicable Interventional

TMS for the Treatment of Pancreatic Cancer Pain

NCT00324428
View directory record Official record
Conditions
Pain, Visceral Pain, Pancreatic Cancer
Interventions
Transcranial Magnetic Stimulation
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV

NCT03692611
View directory record Official record
Conditions
Chronic Pain
Interventions
Skills TO Manage Pain (STOMP), Comparison group
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 89 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

NCT01209871
View directory record Official record
Conditions
Lymphoplasmacytic Lymphoma
Interventions
Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 2 Interventional Results available

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

NCT02647866
View directory record Official record
Conditions
Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Intestinal Diseases, Colonic Diseases, Autoimmune Disease, Abdominal Pain
Interventions
KHK4083, Placebo
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 3 Interventional

SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection

NCT00657566
View directory record Official record
Conditions
Peritonitis
Interventions
duration of antibiotics
Other
Lead sponsor
University of Virginia
Other
Eligibility
16 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 17, 2026, 7:00 PM EDT
Recruiting Not applicable Interventional

Assessment of Gait Adaptation Due to an Asymmetric Walking Protocol

NCT05968729
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
Active Comparator: 0.25 m/s asymmetric session first, Active Comparator: 0.50 m/s asymmetric session first
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 17, 2026, 7:00 PM EDT
Recruiting Not applicable Interventional

Comparison of Smartphone and Community-Based Delivery of the Otago Exercise Program for Fall Risk in Older Adults

NCT07433153
View directory record Official record
Conditions
Frail Elderly, Fall
Interventions
Smartphone-Based Intervention, Group-Based Intervention
Behavioral
Lead sponsor
Binghamton University
Other
Eligibility
55 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SMLI With Hispanic Cancer Survivors and Caregivers

NCT05364372
View directory record Official record
Conditions
Cancer Survivors, Cancer
Interventions
Symptom assessment only, Symptom management and lifestyle intervention
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 17, 2026, 7:00 PM EDT
Recruiting Not applicable Interventional

Digital Dyadic Family Based Intervention to Improve Sleep in Children with ODD and Their Parents: NiteCAPP SINCC (Pilot)

NCT06410495
View directory record Official record
Conditions
Oppositional Defiant Disorder, Insomnia Chronic
Interventions
NiteCAPP SINCC
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 17, 2026, 7:00 PM EDT
Active, not recruiting Phase 3 Interventional

ACHIEVE Brain Health Follow-Up Study

NCT05532657
View directory record Official record
Conditions
Aging, Cognitive Decline, Mild Cognitive Impairment, Dementia, Hearing Loss
Interventions
Hearing intervention, Successful aging/delayed hearing intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
73 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Hagerstown, Maryland • Minneapolis, Minnesota • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 17, 2026, 7:00 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Developing a Healthy Lifestyle in Breast Cancer Survivors

NCT02677857
View directory record Official record
Conditions
Breast Cancer, Sedentary Lifestyle
Interventions
Common intervention components for Lifestyle
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 17, 2026, 7:00 PM EDT
Terminated Phase 2 Interventional

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

NCT03795428
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046) Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 17, 2026, 7:00 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

NCT02665065
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions
Iomab-B, Conventional Care, HCT
Drug · Procedure
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 3 Interventional Results available

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

NCT00280566
View directory record Official record
Conditions
Bipolar Mania, Bipolar Disorder
Interventions
Placebo, Ziprasidone Oral Capsule
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
73
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

NCT00942851
View directory record Official record
Conditions
Focal Dystonia
Interventions
Acetyl-Hexapeptide Topical Treatment, placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)

NCT02602353
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
Loxoprofen Pain Patch, Placebo Patch, No Treatment
Drug
Lead sponsor
Lead Chemical Co., Ltd.
Industry
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 17, 2026, 7:00 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Imaging Speech in Neurotypical Adults and Individuals With Cerebellar Stroke

NCT06458153
View directory record Official record
Conditions
Stroke, Cerebellum
Interventions
Neural responses to speech functional localizer, Neural responses to silent articulation, Neural responses to self vs. externally generated speech, Event-related potentials for speech, Neural responses to induced speech errors, Neural responses to sensory-motor adaptation, Speech production behaviors, Auditory acuity testing, Neural responses to learning a non-speech auditory motor behavior
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity and Social-media Support

NCT04744077
View directory record Official record
Conditions
Trust
Interventions
Influencer Instagram account, Research study Instagram account
Behavioral
Lead sponsor
California State Polytechnic University, Pomona
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

NCT02026401
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
NGM282, Placebo
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 17, 2026, 7:00 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Angiotensin-(1-7) Cardiovascular Effects in Aging

NCT05301192
View directory record Official record
Conditions
Aging
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 7:00 PM EDT
Terminated Phase 2 Interventional Results available

Org 24448 to Treat Major Depression

NCT00113022
View directory record Official record
Conditions
Depression
Interventions
Org 24448, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 17, 2026, 7:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

NCT03199339
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBA-7371, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 17, 2026, 7:00 PM EDT